krinaj@gmail.com

Translational PBPK-QSP Platforms for Tuberculosis Drug Development

Leave a Comment / Mechanistic Modeling, QSP /

Animal models have long served as the preclinical gatekeeper for tuberculosis drug development, yet they systematically fail to predict human pharmacokinetics, efficacy, and toxicity—a translation gap that has left TB drug discovery inefficient, costly, and ethically burdensome. Quantitative systems pharmacology (QSP) modeling frameworks enable researchers to evaluate host-directed therapies (HDTs) against Mycobacterium tuberculosis by mechanistically […]

Translational PBPK-QSP Platforms for Tuberculosis Drug Development Read More »

Weight of Evidence Approach for Waiving Long Term Toxicity Studies for Monoclonal Antibodies

Leave a Comment / Strategy /

A paper by FDA authors [Hao et al., 2026] systematically evaluated the contribution of chronic 6-month non-human primates (NHP) toxicity studies to human safety assessment for monoclonal antibodies (mAbs). Three key points stand out: • Long-term NHP toxicity studies rarely altered regulatory conclusions regarding human risk. • Long-term studies generally did not identify unexpected off-target

Weight of Evidence Approach for Waiving Long Term Toxicity Studies for Monoclonal Antibodies Read More »

Physiologically-Based Pharmacokinetic (PBPK) Models

Leave a Comment / Mechanistic Modeling, Pharmacokinetic Modeling /

PBPK is a computational approach that predicts how a drug moves through the body—how it is absorbed, distributed, metabolized, and eliminated. Unlike traditional methods that rely heavily on animal studies, PBPK models can use lab-based (in vitro) and physicochemical property data to simulate drug behavior in humans before any in vivo testing. This makes PBPK

Physiologically-Based Pharmacokinetic (PBPK) Models Read More »